China gene editing startup YolTech raised $70 million, its biggest funding round to date, as it pushes CRISPR therapies forward and looks toward an eventual Hong Kong IPO. The financing underscores continued investor interest in editing-first pipelines despite the industry’s higher bar for clinical evidence. YolTech joins a growing set of China-based gene editing firms scaling development programs while managing regulatory and manufacturing constraints typical for advanced biologics. The raise also signals confidence that the company’s preclinical or early-stage assets can translate into differentiated clinical development paths. For the biotech ecosystem, the deal matters because capital allocation is one of the clearest indicators of where execution risk is being priced down—specifically for editing modality companies seeking to move into later-stage testing. Near-term catalysts are expected to include advancement milestones tied to the company’s CRISPR programs and clearer IPO timing as clinical and operational milestones accumulate.